Novo Nordisk Foundation signs research and development agreement on global health issues


The Novo Nordisk Foundation, Wellcome and the Bill and Melinda Gates Foundation signed a $300 million research and development initiative focused in part on infectious diseases and antimicrobial resistance.

According to the May 6 release, the trio is tackling multiple global health challenges, particularly those affecting more vulnerable populations. The three-year partnership includes a $100 million investment by both parties that will be used for research and development aimed at addressing the health impacts of climate change; infectious diseases; and better understanding of the interactions between nutrition, immunity, disease and developmental outcomes. .

The ultimate goal of this collaboration is to advance solutions that are accessible and affordable for people living in low- and middle-income countries. Funding will include direct support to researchers and institutions in these countries, including resources to advance relevant local research agendas and build R&D capabilities.

When focusing on infectious diseases, special attention will be given to addressing antimicrobial resistance, advancing disease surveillance, and developing vaccines for respiratory infections.

“By bringing together each organization’s deep experience and unique expertise in research, technology, innovation and enterprise, we can achieve advances that would otherwise be impossible,” said Dr. Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation. in a press release. ā€œIā€™m particularly excited about the opportunity to break down barriers between often siled areas of work ā€“ such as those between cardiometabolic diseases and infectious diseases, or between scientific discovery and solution delivery ā€“ and support the development of real Innovative solutions that improve and save lives.

An influx of cash in 2023 related to Novo Nordisk’s GLP agonist Wegovy means increased interest in the broader Novo brand, including the not-for-profit Novo Nordisk Foundation.

In October 2023, Thomson told Fierce Biotech that his self-proclaimed foundation’s mission was to consolidate the organization’s disparate research efforts and make it “more mission-driven and more strategic.”

Over the past few years, the philanthropic giant has teamed up with the Bill & Melinda Gates Foundation to develop new antiviral drugs to prevent future pandemics and how to use carbon dioxide to produce proteins for human food.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top